hormone glp 1 Glucagon-like peptide-1 receptor: mechanisms and advances in therapy Doctor explains: How diet, sleep

130 In BMSCs and preosteoblast MC3T3-E1 cells, miR-376b-3p directly targets YAP1 to suppress YAP1 expression, and circ_0024097 serves as a ceRNA to rescue YAP1 by absorbing miR-376b-3p, leading to activation of the Wnt/-catenin signalling pathway and cell differentiation, which attenuates osteoporosis

Once reconstituted with bacteriostatic water, store the vial at 28C (refrigerator) and use within 28 days beyond this window, peptide degradation accelerates even under refrigeration

All measures to prevent PCR contamination were strictly applied

How to Switch The transition is straightforward: Stopping Saxenda: No taper required Can stop after last daily dose No withdrawal effects Starting semaglutide: Begin at starting dose (0.25mg weekly) Follow standard titration schedule Some providers start at higher doses for patients switching from other GLP-1s, but standard titration is safest Timing: Can start semaglutide the week after stopping Saxenda No mandatory washout period Some providers start immediately after last Saxenda dose What to Expect During transition: Appetite suppression may temporarily decrease during early semaglutide titration GI side effects may recur as you adjust to new medication Full semaglutide effect takes 4-5 months to reach After transition: Most patients see additional weight loss beyond what Saxenda achieved Weekly dosing is typically more convenient Similar ongoing management Transition Considerations Timing expectations: Dont expect immediate additional weight loss Titration period is necessary even for patients experienced with GLP-1s Full benefit of switch becomes apparent at maintenance doses Managing expectations: Some initial adjustment period is normal The convenience benefit is immediate Weight loss benefit develops over months Practical Considerations for Each Medication Understanding day-to-day use helps set expectations